Regulators split on antimalarials for COVID-19

Lancet. 2020 Apr 11;395(10231):1179. doi: 10.1016/S0140-6736(20)30817-5.
No abstract available

Publication types

  • News

MeSH terms

  • Antimalarials / adverse effects*
  • Antimalarials / supply & distribution
  • Antimalarials / therapeutic use
  • Betacoronavirus
  • COVID-19
  • Chloroquine / adverse effects*
  • Chloroquine / supply & distribution
  • Chloroquine / therapeutic use
  • Coronavirus Infections / drug therapy*
  • Coronavirus Infections / epidemiology
  • Drug Approval / legislation & jurisprudence*
  • Drug Approval / organization & administration
  • European Union
  • Humans
  • Hydroxychloroquine / adverse effects*
  • Hydroxychloroquine / supply & distribution
  • Hydroxychloroquine / therapeutic use
  • Pandemics / legislation & jurisprudence
  • Pneumonia, Viral / drug therapy*
  • Pneumonia, Viral / epidemiology
  • SARS-CoV-2
  • United States / epidemiology

Substances

  • Antimalarials
  • Hydroxychloroquine
  • Chloroquine